What is the next generation therapeutic strategy for castration-resistant prostate cancer - Abstract

Prostate cancer (PCa) is one of the most common cancers in the world.

Since androgen receptor (AR) signal plays key roles in the PCa progression, targeting androgens via the current androgen deprivation therapy (ADT) is the main therapeutic strategy for advanced PCa. However, most patients who receive ADT, including the second generation anti-androgens enzalutamide (also known as MDV3100) may finally develop the castration (or anti-androgen) resistance after 12-24 months treatment. In the manuscript by Asangani et al., the authors demonstrated that targeting the amino-terminal bromodomains of BRD4 could preferentially suppress human castration-resistant prostate cancer (CRPC) cell lines. While further studies are required to understand the full impact of their findings, the innovative approach provides a potential novel epigenetic approach for the concerted blockade of oncogenic drivers in CRPC.

Written by:
Wen SM, Quan CY, Jiang N, Shang ZQ, Niu YJ.   Are you the author?
Department of Urology, Second Hospital of Tianjin Medical University; Chawnshang Chang Sex Hormone Research Center, Tianjin Institute of Urology, Tianjin Medical University, Tianjin, China.

Reference: Asian J Androl. 2014 Nov 18. Epub ahead of print.
doi: 10.4103/1008-682X.143311

PubMed Abstract
PMID: 25432503

UroToday.com Prostate Cancer Section